SAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing tuspetinib, a highly differentiated oral kinase inhibitor for the treatment of patients with acute myeloid leukemia (AML), announced the voting results from its special meeting of shareholders held today, September 5, 2024 (the "Meeting").
A total of 6,052,460 common shares of the Company (the "Shares"), representing 33.42% of the issued and outstanding Shares were voted at the Meeting.
The proposals put forward before the Company's shareholders for consideration and approval, as set out in the Company's definitive proxy statement dated July 11, 2024 (the "Proxy Statement"), were approved by the requisite number of votes cast at the Meeting, as further detailed below:
- Proposal No. 1 - passing a resolution, the full text of which is set forth in the Proxy Statement, approving the issuance of common shares of the Corporation underlying certain warrants pursuant to Nasdaq Listing Rules; and
- Proposal No. 2 - passing a resolution, the full text of which is set forth in the Proxy Statement, approving one or more adjournments of the Meeting, if necessary or appropriate, if a quorum is present, to permit further solicitation of proxies if there are not sufficient votes at the time of the Meeting to approve Proposal No. 1.
Please refer to the Company's Proxy Statement available on SEDAR+ at www.sedarplus.ca or EDGAR https://www.sec.gov/edgar.shtml for more details on the matters covered at the Meeting. Final voting results on all matters voted on at the Meeting will also be filed on SEDAR+ and EDGAR.
The detailed results of the vote at the Meeting are set out below:
| APTOSE BIOSCIENCES INC. ADJOURNED SPECIAL MEETING OF SHAREHOLDERS HELD ON SEPTEMBER 5, 2024 REPORT ON PROXIES | ||||||||
| MOTIONS | NUMBER OF SHARES | PERCENTAGE OF VOTES CAST | ||||||
| FOR | AGAINST | WITHHELD/ ABSTAIN | RESTRICTED | NON VOTE | FOR | AGAINST | WITHHELD/ ABSTAIN | |
| Approval of Nasdaq 20% Issuance Proposal | 3,969,105* | 267,013 | 16,342 | 1,800,000 | 0 | 93.34% | 6.28% | 0.38% |
| Multiple Adjournments | 5,873,779 | 138,958 | 39,722 | 1 | 97.05% | 2.30% | 0.66% | |
| * Excluding 1,800,000 shares held by Insiders | ||
| TOTAL SHAREHOLDERS VOTED BY PROXY: | 47 | |
| TOTAL SHARES ISSUED & OUTSTANDING: | 18,109,393 | |
| TOTAL SHARES VOTED: | 6,052,460 | |
| TOTAL % OF SHARES VOTED: | 33.42% | |
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company's lead clinical-stage compound tuspetinib (TUS), is an oral kinase inhibitor that has demonstrated activity as a monotherapy and in combination therapy in patients with relapsed or refractory acute myeloid leukemia (AML) and is being developed as a frontline triplet therapy in newly diagnosed AML. For more information, please visit www.aptose.com.
For further information, please contact:
Aptose Biosciences Inc.
Susan Pietropaolo
Corporate Communications & Investor Relations
201-923-2049
spietropaolo@aptose.com
